Simulations Plus Releases ADMET Predictor® Version 9.5
April 11 2019 - 8:30AM
Business Wire
New machine learning models and novel
analysis methods address customer requests
Simulations Plus, Inc. (Nasdaq:SLP), the leading provider of
modeling and simulation solutions for the pharmaceutical,
biotechnology, chemicals, and consumer goods industries, today
announced that it has released version 9.5 of its flagship machine
learning modeling platform, ADMET Predictor®.
Key improvements include:
- Novel approaches to calculate
uncertainty estimates on all regression models
- New machine learning models for
important metabolism and transporter endpoints
- New machine learning models for AMES
mutagenicity, a primary toxicity endpoint required during risk
assessment
- New Structure Sensitivity Analysis
visualization tool to easily map atom-level contributions to model
predictions
- Improved rat-specific models to more
accurately inform HTPK Simulation predictions
- Improved Pipeline Pilot and KNIME
components to extend deployment options and enterprise support for
ADMET Predictor
- Updates to output displays in MedChem
Designer™
- And more…
Dr. David Miller, director of ADMET cheminformatics, said: “Our
team of talented scientists and software engineers introduced a
significant amount of innovative functionality, not available in
other software, in this release of ADMET Predictor. In particular,
the ability of chemists to now ‘see’ how a molecule could be
optimized for important ADMET properties tells a story that can be
easily communicated across departments as research programs
progress. This further establishes our machine learning platform as
an industry leader and will be welcomed by clients.”
Lancaster division president, John DiBella, added: “We continue
to realize solid growth in the number of companies, from small to
large, and regulatory agencies that license ADMET Predictor. Our
best-in-class machine learning methods are now being applied to
more enzyme and transporter isoforms, which, when paired with our
physiologically-based pharmacokinetic models in GastroPlus®,
provide holistic insights to support discovery research efforts. We
are excited to demonstrate these new features in version 9.5 and,
coupled with recent investments in marketing and sales, expect to
see accelerated expansion of the client base.”
About Simulations Plus, Inc.
Simulations Plus, Inc., is a premier developer of drug discovery
and development software as well as a leading provider of both
preclinical and clinical pharmacometric consulting services for
regulatory submissions and quantitative systems pharmacology models
for drug-induced liver injury, drug-induced kidney injury, and
nonalcoholic fatty liver disease. The company is a global leader
focused on improving the ways scientists use knowledge and data to
predict the properties and outcomes of pharmaceutical,
biotechnology, and chemical agents. Our software is licensed to and
used in the conduct of drug research by major pharmaceutical,
biotechnology, chemical, and consumer goods companies and
regulatory agencies worldwide. Our innovations in integrating new
and existing science in medicinal chemistry, computational
chemistry, pharmaceutical science, biology, and physiology into our
software have made us the leading software provider for
physiologically based pharmacokinetic modeling and simulation. For
more information, visit our website at
www.simulations-plus.com.
Safe Harbor Statement Under the Private Securities Litigation
Reform Act of 1995 – With the exception of historical
information, the matters discussed in this press release are
forward-looking statements that involve a number of risks and
uncertainties. Words like “believe,” “expect” and “anticipate” mean
that these are our best estimates as of this writing, but that
there can be no assurances that expected or anticipated results or
events will actually take place, so our actual future results could
differ significantly from those statements. Factors that could
cause or contribute to such differences include, but are not
limited to: our ability to maintain our competitive advantages,
acceptance of new software and improved versions of our existing
software by our customers, the general economics of the
pharmaceutical industry, our ability to finance growth, our ability
to continue to attract and retain highly qualified technical staff,
our ability to identify and close acquisitions on terms favorable
to the Company, and a sustainable market. Further information on
our risk factors is contained in our quarterly and annual reports
and filed with the U.S. Securities and Exchange Commission.
Follow us on Twitter | LinkedIn
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190411005244/en/
Simulations Plus Investor
RelationsMs. Renee
Bouche661-723-7723renee@simulations-plus.com
Hayden IRMr. Cameron
Donahue651-653-1854cameron@haydenir.com
Simulations Plus (NASDAQ:SLP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Simulations Plus (NASDAQ:SLP)
Historical Stock Chart
From Apr 2023 to Apr 2024